Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

Abstract:
NanoLogix, Inc. (PINKSHEETS: NNLX) announced today that it has filed a provisional patent application with the U.S. Patent Office titled, "Antimicrobial Action of a Silver-Coated Nanotubular Dialysis Device."

NanoLogix Applies for Provisional Patent Application For Innovative Treatment of Severe Sepsis

SHARON, PA | Posted on February 20th, 2007

This provisional patent application is based around a new and unique methodology for treating severe sepsis and septic shock. The incidence of severe sepsis and septic shock is the major factor in over two hundred thousand deaths per year in the United States. During the past decades billions of dollars have been spent in developing treatment strategies for this major cause of morbidity and mortality. Almost all treatment strategies have been centered around the utilization of intravenous antibiotics. However, even today 20-35% of patients with severe sepsis and 40-60% of patients with septic shock die within thirty days, with further deaths occurring within the first six months of illness. Due to the fact that almost all of these patients must be treated in intensive care units, the cost of treating a single patient costs up to $10,000 per day, and the total cost to the American health care system is many billions of dollars per annum.

The NanoLogix invention treats bacteremia and septic shock by utilizing a silver nanoparticle-coated nanotubular dialysis unit for killing pathogenic micro-organisms present in a patient's blood stream. Prior to making this application NanoLogix scientists investigated this novel methodology against two bacterial strains (E.coli and Staphylococcus aureus) and one fungal strain (Candida albicans). In multiple experiments the pathogenic load of the micro-organisms went from colonies that were too numerous to count, down to zero or a very dramatically reduced number of colonies.

Mitchell S. Felder, M.D., the CEO and Chairman of the Board of NanoLogix, Inc. stated, "This is both a fascinating as well as truly innovative approach to conquering this major cause of hospital deaths worldwide. We hope to accelerate our investigation of this methodology, and are currently seeking to partner with a major university and/or health care organization. With further success and development, this technique could truly revolutionize the treatment of infectious diseases and save countless lives."

####

About NanoLogix
NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32 patented technologies. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious human diseases such as cancer, cystic fibrosis and AIDS, and owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit http://www.nanologix.net.

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please click here

Contacts:
Investor Relations.
Andrew Barwicki
516.662.9461

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Researchers peer into atom-sized tunnels in hunt for better battery: May improve lithium ion for larger devices, like cars December 8th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Patents/IP/Tech Transfer/Licensing

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

Energy

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Physics, photosynthesis and solar cells: Researchers combine quantum physics and photosynthesis to make discovery that could lead to highly efficient, green solar cells November 30th, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project